Dizal (Jiangsu) Pharmaceutical 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Zhang Xiaolin

최고 경영자

CN¥9.5m

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	1.8%
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	4.2yrs

최근 관리 업데이트

Recent updates

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Aug 20

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

May 02

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Apr 30

CEO

Zhang Xiaolin (60 yo)

no data

테뉴어

CN¥9,534,800

보상

Dr. Zhang Xiaolin Ph.D. is General Manager and Chairman of Dizal (Jiangsu) Pharmaceutical Co., Ltd. and served as its Chief Scientist. Dr. Xiaolin joined the Dizal (Jiangsu) Pharmaceutical Co., Ltd.in 201...

리더십 팀

이름	위치	테뉴어	보상	소유권
Zhang Xiaolin	GM & Chairman	no data	CN¥9.53m	1.76% CN¥ 353.7m
Lyu Hongbin	CFO & Board Secretary	4.8yrs	CN¥4.07m	데이터 없음
Zhiwei Zhang	Deputy GM	1.3yrs	CN¥1.81m	0.024% CN¥ 4.8m
Qingbei Zeng	Deputy GM	no data	CN¥2.03m	0.072% CN¥ 14.5m
Zhenfan Yang	Deputy GM & Chief Medical Officer	no data	CN¥3.59m	1.09% CN¥ 219.5m
Qingyi Wu	Deputy GM & Chief Commercial Officer	no data	CN¥5.23m	0.0028% CN¥ 571.1k
Honchung Tsui	Deputy GM	1.3yrs	CN¥2.31m	0.072% CN¥ 14.5m
Shih-Ying Chang	Deputy GM	no data	CN¥2.76m	0.0096% CN¥ 1.9m
Suqin Chen	Deputy GM & Senior VP of Clinical Operations	no data	CN¥2.98m	0.11% CN¥ 22.2m
Weijun Qiao	VP & Head of Registration Affairs	1.3yrs	CN¥1.98m	0.048% CN¥ 9.7m
Kan Chen	Vice President of Clinical Pharmacology	no data	CN¥1.72m	0.0072% CN¥ 1.5m
Xiaojing Kang	Employee Supervisor & Head of Accounting Agency	no data	데이터 없음	0.0041% CN¥ 822.5k

1.3yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 688192 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zhang Xiaolin	GM & Chairman	no data	CN¥9.53m	1.76% CN¥ 353.7m
Xiaojing Kang	Employee Supervisor & Head of Accounting Agency	2.8yrs	데이터 없음	0.0041% CN¥ 822.5k
Guanshan Zhu	Independent Director	4.2yrs	CN¥100.00k	데이터 없음
Simon Dazhong Lu	Director	7.8yrs	데이터 없음	데이터 없음
Rodolphe Peter Andre Grepinet	Director	7.8yrs	데이터 없음	데이터 없음
Jiang Bin	Independent Director	4.2yrs	CN¥100.00k	데이터 없음
Wang Xuegong	Independent Director	4.2yrs	CN¥100.00k	데이터 없음
Zhang Xin	Independent Director	4.2yrs	CN¥100.00k	데이터 없음
Dong Weiwen	Chairman of the Supervisory Board	no data	데이터 없음	데이터 없음
Yuan Sun	Supervisor	no data	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: 688192 의 이사회는 경험(평균 재직 기간 4.2 년)으로 간주됩니다.

Dizal (Jiangsu) Pharmaceutical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Insufficient new directors

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Price target increased by 7.4% to CN¥56.00

Dizal Receives Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

NMPA Approves Burning Rock and Dizal's First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dizal Announces the National Medical Products Administration of China Approves Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

New minor risk - Share price stability

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Latest Data from the Inaugural Global Pivotal Study WU-KONG1 Part B (WU-KONG1B) of Sunvozertinib in Relapsed or Refractory Non-Small Cell Lung Cancer

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Consensus revenue estimates decrease by 12%

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

New major risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

New minor risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

Consensus EPS estimates fall by 13%

New major risk - Share price stability

Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients

Insufficient new directors

Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology

New major risk - Revenue and earnings growth

Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Compelling Data of Its Robust Oncology Portfolio At the 2023 American Society of Clinical Oncology Annual Meeting

Price target increased by 11% to CN¥56.42

Dizal Announces Center for Drug Evaluation Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

Less than half of directors are independent

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 WCLC

Dizal Pharmaceutical Announces Pre-Clinical and Clinical Results of Sunvozertinib (DZD9008) Published in Cancer Discovery

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for Dzd4205 for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 (Sunvozertinib) for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령